New 1-benzhydryl-3-phenylurea derivatives and their 1-benzhydryl-3-phenylthiourea isosteres were synthesized and evaluated for their human CB 1 and CB 2 cannabinoid receptor affinity. These compounds proved to be selective CB 1 cannabinoid receptor ligands, acting as inverse agonists in a [ 35 S]-GTPγS assay. The affinity of 3,5,5′-triphenylimidazolidine-2,4-dione and 3,5,5′-triphenyl-2-thioxoimidazolidin-4-one derivatives, possessing the 1-benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea moiety, respectively, was also evaluated. In conclusion, the 1-benzhydryl-3-phenylurea scaffold seems to be a new interesting template of CB 1 cannabinoid receptor inverse agonists.
Introduction
The synthesis of the first potent CB 1 cannabinoid receptor antagonist/inverse agonist SR141716A 1 (rimonabant) and the breeding of knock-out CB 1 mice 2, 3 confirmed the high therapeutic potential for modulating CB 1 cannabinoid receptor activity. Several CB 1 cannabinoid receptor inverse agonists were shown to reduce food intake, 4,5 ethanol consumption, 6 and nicotine reward 7, 8 in animals. Other studies suggested a beneficial effect on septic shock in rats 9 and in gastrointestinal disorders. 10 Subsequent phase II or III clinical trials confirmed the usefulness of such compounds in treating obesity 11, 12 and nicotine 11 addictions. Among the cannabinoid receptor antagonists/inverse agonists available, most are constructed around a central heterocyclic ring (pyrazole, triazole, indole, imidazolidinedione, or thioxoimidazolidinone) bearing further substituted aromatic rings. 13 In this paper, we report the CB 1 cannabinoid receptor inverse agonist properties of new compounds that are not built around such a central ring. The 1-benzhydryl-3-phenylurea derivatives described herein exhibited interesting affinities and potencies for the CB 1 cannabinoid receptor. The 1-benzhydryl-3-phenylthiourea isosteres also showed affinity and inverse agonist properties at the CB 1 cannabinoid receptor. The compounds were then compared with the corresponding 3-phenyl-5,5′-diphenylimidazolidine-2,4-dione and 3-phenyl-5,5′-diphenyl-2-thioxoimidazolidin-4-one derivatives.
Results and Discussion
Chemistry. Benzoin condensation starting from substituted benzhaldehydes was used for the synthesis of the substituted benzils (1) . Phenylurea (2, X′ ) O) and phenylthiourea (2, X′ ) S) derivatives were easily synthesized from the corresponding aniline and phenylisothiocyanate, respectively (Scheme 1). Target 1-benzhydryl-3-phenylurea derivatives (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) were obtained by reaction of the respective benzil (1) and phenylurea (2, X′ ) O), following a microwave-enhanced method previously described 14 (Scheme 1). The corresponding thio derivatives (22-25) were obtained similarly by reacting 1 and phenylthiourea (2, X′ ) S). The synthesis of the thio derivatives, reported here for the first time, will allow the oxo and thio isostere comparison at the CB 1 and CB 2 cannabinoid receptors. The 3,5,5′-triphenylimidazolidine-2,4-dione (26-29) and 3,5,5′-triphenyl-2-thioxoimidazolidin-4-one derivatives (30, 31) were obtained by reaction of 1 and phenylurea (2, X′ ) O) or phenylthiourea (2, X′ ) S) in ethanol in the presence of ethanolate (Scheme 2).
Pharmacology. An initial screening, performed at 10 µM, using human CB 1 1 or CB 2 cannabinoid receptors, respectively, allowed the establishment of some preliminary structure-affinity relationships (Table 1) . First, the benzhydryl moiety must be substituted to achieve CB 1 cannabinoid receptor affinity. Indeed compounds 3, 4, and 6-9 displaced less than 25% of [ 3 H]-SR141716A specific binding. Furthermore, the preferred benzhydryl substitutents are chlorine (12) and bromine (13) . Second, comparing the radioligand displacements obtained with 14-21 revealed that chlorine and bromine are the preferred substituents for the phenyl moiety as well. Compounds 3-21 showed only poor displacement of the CB 2 cannabinoid receptor bound radioligand ([ 3 H]-CP-55,940). K i values of 12-18, which showed the highest radioligand displacement at 10 µM at the CB 1 cannabinoid receptor, were obtained ( Table  1) . Substitution of the phenyl moiety (X 2 in Scheme 1) greatly increased the affinity for the CB 1 cannabinoid receptor as illustrated by 12 (K i ) 7050 ( 550 nM) and 14 (K i ) 1100 ( 100 nM) or by 13 (K i ) 2900 ( 250 nM) and 16 (K i ) 650 ( 50 nM). With respect to the bromobenzhydryl derivatives (13, 16, 17, 19-21) , the bromine substituent (X 2 in Scheme 1) proved to be the preferred substituent at the para position of the phenyl ring (17, K i ) 500 ( 50 nM). Smaller and larger halogen atoms resulted in decreased affinity, as illustrated by 16 (K i ) 650 ( 50 nM) and 19 (32 ( 2% of displacement at 10 µM), respectively. Replacing the bromobenzhydryl (X 1 in Scheme 1) by a chlorobenzhydryl (15, K i ) 1250 ( 100 nM) or an iodobenzhydryl (18, K i ) 750 ( 100 nM) moiety also decreased the affinity. Four 1-benzhydryl-3-phenylthioureas (22-25) were obtained to estimate the effect of the oxygen-sulfur substitution ( Table  1 ). The affinity of the unsubstituted 3-phenyl derivatives was increased by the replacement of the oxygen atom by the sulfur as illustrated by 12 (K i ) 7050 ( 550 nM) and 22 (K i ) 2900 ( 250 nM) or by 13 (K i ) 2900 ( 250 nM) and 23 (K i ) 1800 ( 150 nM). However, the affinity of the substituted 3-phenyl derivatives (X 2 in Scheme 1) is decreased for the thio derivatives as shown by 14 (K i ) 1100 ( 100 nM) and 24 (K i ) 1900 ( 200 nM) or by 16 (K i ) 650 ( 50 nM) and 25 (K i ) 1500 ( 150 nM). Thus, replacement of the oxygen by a sulfur atom in 1-[bis(4-bromophenyl)methyl]-3-(4-chlorophenyl)urea (16) resulted in decreased affinity.
We previously described the structure-affinity relationships at the CB 1 cannabinoid receptor of alkyl and alkylaryl 3-substituted 5,5′-diphenylimidazolidine-2,4-diones 15 and 5,5′-diphenyl-2-thioxoimidazolidin-4-ones 16 as selective CB 1 cannabinoid receptor inverse agonists. Therefore, four 3,5,5′-triphenylimidazolidine-2,4-diones (26-29) and two 3,5,5′-triphenyl-2-thioxoimidazolidin-4-one derivatives (30, 31) were synthesized (Scheme 2) and assayed for their CB 1 cannabinoid receptor affinity ( Table 1 ). The four imidazolidine-2,4-diones assayed at sponding 1-benzhydryl-3-phenylurea and thiourea derivatives, it appears that the orientation of the 1-benzhydryl-3-phenylurea and thiourea phenyl rings imposed by the additional carbonyl led to a decrease in the affinity for the CB 1 cannabinoid receptor. This is illustrated by 13 and 29 (70% and 29% of displacement at 10 µM, respectively) or by 25 and 31 (K i of 1500 ( 150 and 2750 ( 250 nM, respectively).
The 1-benzhydryl-3-phenylurea and thiourea derivatives were further characterized in a functional [ 35 S]-GTPγS assay as previously described. 17 The assay relies on the binding of [ 35 S]-GTPγS, a radiolabeled nonhydrolyzable GTP analogue, to the G protein upon activation by an agonist of the G-protein-coupled receptor. 18 The assay distinguishes between agonists (increasing nucleotide binding), antagonists (not affecting the binding), and inverse agonists (decreasing nucleotide binding). HU-210, a potent cannabinoid agonist, the inverse agonist SR141716A, and the 1-benzhydryl-3-phenylurea and thiourea derivatives 12-18 and 22-25 were screened at 10 µM. In conclusion, the 1-benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives reported here selectively bind to the CB 1 cannabinoid receptor acting as inverse agonists. The structure-affinity relationships highlighted the importance of halogen substituents, especially bromine. Thus, 1-[bis(4-bromophenyl)methyl]-3-(4-bromophenyl)urea (17) exhibited the highest affinity for the CB 1 cannabinoid receptor within this series of compounds. Interestingly, the crucial role of halogen substitution of the phenyl rings is also observed in the structure-affinity relationships of SR141716A and other CB 1 cannabinoid receptor inverse agonists. 13 Finally, despite a lower affinity compared to the affinity of the reference inverse agonist SR141716A, the 1-benzhydryl-3-phenylurea structure constitutes a new, interesting template for CB 1 cannabinoid receptor inverse agonists. Indeed the noncyclic core scaffold CB 1 cannabinoid receptor inverse agonist described herein differs from most of the reported CB 1 cannabinoid receptor antagonists/inverse agonists, which are built around a cyclic central unit.
Experimental Section
All reagents, used without further purification, were purchased from Sigma-Aldrich or Acros. Solvents were of analytical grade. A commercial household microwave oven (2.45 Ghz) was used. Melting points (uncorrected) were determined in open capillaries using an Electrothermal 9100 apparatus. 1 H NMR and 13 C NMR spectra were recorded on a Bruker AM-300 spectrometer at room temperature and analyzed using WIN-NMR software. Chemical shifts (δ) are reported relative to the tetramethylsilane peak set at 0.00 ppm. Signals were abbreviated as follows: s, singlet; d, doublet; t, triplet; m, multiplet. For multiplets, signals are reported as intervals. Coupling constants are expressed in hertz. Mass spectra were recorded on a Finnigan MAT 44S, with an ionization voltage of 70 eV. Elemental analyses were performed on a Carlo Erba EA 1108 analyzer (Carlo Erba, Milano, Italy) and are within (0.4% of the theoretical values. Infrared (IR) spectra (ν in cm -1 ) were recorded on a Perkin-Elmer FT-IR 286 spectrometer (Supporting Information).
Synthesis: General Procedure for the Synthesis of 1-Benzhydryl-3-phenylurea Derivatives. Compounds 3, 5, 7, 11-13, 15, 17, and 19 were previously described. 14 The other 1-benzhydryl-3-phenylurea derivatives were similarly obtained. To a solution of benzil (7.15 mmol) and phenylurea (14.3 mmol) in 25 mL of DMSO was added with stirring 25 mL of 1.2 M aqueous KOH. Following 90 s of 750 W microwave irradiation, the mixture was stirred for an additional 5 min. Additional 30 s pulses were applied at 6, 9, 12, 15, 18, 21, 24, and 30 min. Between pulses, the mixture was stirred. After the completion of the sequence, the mixture was poured onto cold water and the resulting precipitate was filtered, dried, and crystallized. All microwave irradiations were carried out in an open system. Benzhydryl-3-(4-bromophenyl)urea (6 Synthesis of 1-Benzhydryl-3-phenylthiourea Derivatives. The procedure described for the synthesis of 1-benzhydryl-3-phenylurea derivatives was used except that phenylthiourea was substituted for phenylurea. General Procedure for the Synthesis of 3-Substituted 5,5′-Diphenylimidazolidine-2,4-dione Derivatives. Sodium (1 g) was stirred in ethanol (50 mL) for 15 min before benzil (9.5 mmol) and phenylurea (19 mmol) were added. The resulting solution was refluxed for 12 h and after cooling was poured onto ice. The precipitate was filtered, dried, and recrystallized from ethanol. Synthesis of 3-Substituted 5,5′-Diphenyl-2-thioxoimidazolidin-4-one Derivatives. These derivatives were obtained similarly to the 3-substituted 5,5′-diphenylimidazolidine-2,4-dione derivatives starting from the corresponding phenylthiourea. Competition Binding Assay. CHO cells stably expressing the human CB1 or the human CB2 cannabinoid receptors were donated by Drs. M. Detheux and P. Nokin, respectively (Euroscreen s.a., Gosselies, Belgium). Cells membranes were obtained as previously described. 16 Stock solutions of the compounds were prepared in DMSO and further diluted (100×) with the binding buffer to the desired concentration. Under these conditions B max was 57 pmol/mg protein and Kd was 1.13 ( 0.13 nM for the hCB1 cannabinoid receptor ([ Ci/mol, from NEN Life Science, Zaventem, Belgium) as radioligands for the hCB 1 and the hCB2 cannabinoid receptor, respectively, at 30°C in plastic tubes, and 40 µg of membranes per tube was resuspended in 0.5 mL (final volume) of binding buffer (50 mM Tris-HCl, 3 mM MgCl2, 1 mM EDTA, 0.5% bovine serum albumine, pH 7.4). Test compounds were present at varying concentrations, and nonspecific binding was determined in the presence of 10 µM HU-210 (Tocris, Bristol, U.K.). After 1 h of incubation, solutions were rapidly filtered through 0.5% PEI pretreated GF/B glass fiber filters (Whatman, Maidstone, U.K.) on a M-48T Brandell cell harvester and washed twice with 5 mL of ice-cold binding buffer without serum albumin. Radioactivity was measured in a Pharmacia Wallac 1410 -counter in 10 mL of Aqualuma (PerkinElmer, Schaesberg, The Netherlands) after 10 s of shaking and 3 h of resting. Assays were performed at least in triplicate.
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5,5′-Bis(4-bromophenyl)-3-phenyl-2-thioxoimidazolidin-4-one (30)
[ 35 S]-GTPγS Assay. Binding experiments were performed at 30°C in plastic tubes containing 40 µg of protein in 0.5 mL (final volume) of binding buffer (50 mM Tris-HCl, 3 mM MgCl2, 1 mM EDTA, 100 mM NaCl, 0.1% bovine serum albumin, pH 7.4) supplemented with 20 µM GDP and the appropriate concentration of test compounds. The assay was initiated by the addition of [ 35 S]-GTPγS (0.05 nM, final concentration, 1173 Ci/mmol, Amersham, Roosendaal, The Netherlands). Following 1 h of incubation, a total of 5 mL of ice-cold washing buffer (50 mM Tris-HCl, 3 mM MgCl 2, 1 mM EDTA, 100 mM NaCl) was added. The suspension was immediately filtered through GF/B filters using a 48-well Brandell cell harvester and washed twice with the same ice-cold buffer. Radioactivity was counted as mentioned above. Nonspecific binding was measured in the presence of 100 µM Gpp(NH)p. Assays were performed in triplicate.
Data Analysis. IC 50 and EC50 values were determined by nonlinear regression analysis performed using the GraphPad Prism 4.0 software (GraphPad Software, San Diego). The K i values were calculated on the basis of the Cheng-Prusoff equation: Ki ) IC50/(1 + L/Kd).
